Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

Market Cap	11.13B -30.5%
Revenue (ttm)	2.60B +0.3%
Net Income	353.15M -50.4%
EPS	0.36 -51.6%
Shares Out	950.40M
PE Ratio	32.91
Forward PE	11.03
Dividend	0.35 (2.99%)
Ex-Dividend Date	Jun 4, 2025

Volume	8,199,153
Average Volume	7,323,417
Open	11.66
Previous Close	11.68
Day's Range	11.65 - 11.84
52-Week Range	11.56 - 19.13
Beta	0.41
RSI	25.82
Earnings Date	Apr 29, 2026

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human coagulation factor VIII, and human prothrombin complex; and freeze-dried intravenous human immunoglobulin (pH4), human fibrinogen, and intravenous hepat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,755
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2025, SHE:000403's revenue was 2.63 billion, a decrease of -0.83% compared to the previous year's 2.65 billion. Earnings were 419.27 million, a decrease of -43.75%.